MAPT and Alzheimer disease: In a recent primary prevention study, prenatal to early postnatal treatment with P021 was found to prevent cognitive deficits, AD-type pathological changes, which include tau and Aβ pathologies, postsynaptic deficit, and neuroinflammation later in life in 3xTg mice [197].